Physician profile
Jonathan P Martinez
NPI 1679764450
$6,358.20
in general payments reported to CMS, 2019-2025
28 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $61.06 · 2021: $191 · 2022: $1,103 · 2023: $1,386 · 2024: $1,646 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,751 · Education: $21.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,751.17 |
| Education | $21.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,082.72 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $762.73 | 2021-2025 | Biktarvy |
| Novo Nordisk INC | $660.46 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $562.07 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $442.91 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $432.20 | 2022-2025 | Verquvo, Pifeltro, Delstrigo |
| Lilly USA, LLC | $177.31 | 2022-2024 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $160.02 | 2019-2023 | Symtuza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.01 | 2021-2025 | Jardiance, Synjardy |
| Lundbeck LLC | $136.79 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Indivior INC. | $115.00 | 2023-2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $72.67 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $64.53 | 2020-2022 | |
| Amgen INC. | $60.36 | 2023-2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $60.32 | 2022-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.46 | 2019-2025 | Airsupra |
| Dexcom, INC. | $48.01 | 2022-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $43.67 | 2019 | |
| Glaxosmithkline, LLC. | $41.17 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $34.87 | 2025 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $34.82 | 2024 | Voquezna |
| Shield Therapeutics INC | $33.90 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $33.62 | 2023 | Gvoke Hypopen |
| Alkermes, INC. | $29.22 | 2024 | Vivitrol |
| Braeburn INC. | $22.41 | 2025 | Brixadi |
| Phadia US INC. | $19.97 | 2024 | Immunocap |
| Janssen Pharmaceuticals, INC | $15.64 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.